Armistice Capital LLC Cuts Stock Holdings in Hoth Therapeutics, Inc. (NASDAQ:HOTH)

Armistice Capital LLC lowered its position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 48.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 213,000 shares of the company’s stock after selling 197,000 shares during the period. Armistice Capital LLC owned about 3.97% of Hoth Therapeutics worth $194,000 at the end of the most recent reporting period.

Hoth Therapeutics Price Performance

NASDAQ HOTH opened at $0.88 on Friday. The business’s fifty day moving average is $0.82 and its 200-day moving average is $1.03. The stock has a market capitalization of $6.07 million, a price-to-earnings ratio of -0.45 and a beta of 0.82. Hoth Therapeutics, Inc. has a one year low of $0.58 and a one year high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.15. Research analysts expect that Hoth Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOTH has been the subject of a number of recent analyst reports. EF Hutton Acquisition Co. I raised shares of Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a report on Friday, August 16th.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.